Proactiveinvestors Australia

GI Dynamics www.gidynamics.com/index.php

GI Dynamics (ASX: GID) is a company focused on the development and commercialisation of effective, non-surgical treatments targeting the large and growing global patient populations with type 2 diabetes and obesity.
Pdf

GI Dynamics to collaborate with GlaxoSmithKline, Medtronic on diabetes and obesity treatment

Friday, January 04, 2013 by Proactive Investors

 GI Dynamics to collaborate with GlaxoSmithKline, Medtronic on diabetes and obesity treatment

Medical device maker GI Dynamics (ASX:GID) has entered into two separate research collaborations with GlaxoSmithKline (NYSE:GSK) and Medtronic (NYSE:MDT) to evaluate its EndoBarrier treatment for type 2 diabetes and obesity.

The collaboration with Medtronic is focused on understanding how EndoBarrier impacts continuous glucose levels, while with GSK the research will evaluate hormonal changes in response to EndoBarrier Therapy to further characterize the mechanism of action of the EndoBarrier.

EndoBarrier is a thin, flexible, tube-shaped liner that forms a physical barrier between food and a portion of the wall of the intestine. In 13 clinical studies involving more than 500 patients, EndoBarrier has been shown to achieve rapid reductions in blood sugar levels and weight loss of approximately 20 percent in 12 months.

It is hoped the collaboration could lead to improvements in the device as well as potential combinations of drug treatment and EndoBarrier Therapy and optimise patient outcomes.

EndoBarrier is considered an investigational new device in the US, while it has received CE Mark approval in Europe in 2010 and the approval by the Therapeutic Goods Administration in Australia in 2011 for the treatment of type 2 diabetes or obesity for up to 12 months.

The device is entering a clinical trial phase in the US and is commercially available in many European countries including Germany, Austria, the United Kingdom and the Netherlands. It is also available in Australia and Chile.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Sign up to Proactive Investors

Andrew McCrea's Research Reports
Sign up to Andrew McCrea's Research Reports and Receive Latest Research & Flash Trades
Receive Proactive Investors Newsletter, Investor Forum Invites
Receive Proactive Investors Newsletter, Event Invites, Special Stock Notifications

Comments from Proactive Investors readers

  • Fill in your details below:
Verification Code
Andrew McCrea is Sub Authorised Representative (SAR: 291331) of Proactive Investors Australia Pty Ltd
(ABN: 19 132 787 654) which is a Corporate Auhorised Representative (CAR: 413802) of RM Capital
Pty Ltd (AFSL: 221938).

Copyright © proactiveinvestors.com.au, 2012. All Rights Reserved